Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Sci Transl Med. 2022 Mar 16;14(636):eabl5399. doi: 10.1126/scitranslmed.abl5399

Fig. 7: In vivo protective efficacy of human nAbs in a PUUV bank vole challenge model.

Fig. 7:

(A) Bank voles were administered a single 25 mg/kg dose (i.p.) of the indicated nAbs (n=12 from two experiments) or PBS vehicle (n=9 from two experiments) followed by a challenge with PUUV/Suo (500 FFU, s.c.) at 4 h post nAb administration. Animals were sacrificed at 3 days post challenge and serum and organ viral RNA loads were determined by RT-qPCR detecting the PUUV S segment. Bars indicate median. (B) Bank voles were challenged with PUUV/Suo (500 FFU, s.c.) followed by treatment with a single 25 mg/kg dose (i.p.) of the indicated nAbs (n=12 from two experiments) or PBS vehicle (n=11 from two experiments) at 24 h post challenge. Animals were sacrificed at 3 days post challenge, and viral RNA loads were determined as above. Bars indicate median. Untreated versus nAb-treated animals, un-paired Kruskal-Wallis test: **, P=0.0021; ***, P=0.0002; ****, P<0.0001.